B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Multicentre, Randomized, Double-blind and Placebo Controlled Phase-III Study With Rituximab Induction and Maintenance Treatment.

Trial Profile

B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Multicentre, Randomized, Double-blind and Placebo Controlled Phase-III Study With Rituximab Induction and Maintenance Treatment.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2016

At a glance

  • Drugs Rituximab (Primary)
  • Indications Chronic fatigue syndrome
  • Focus Therapeutic Use
  • Acronyms RituxME
  • Most Recent Events

    • 11 Apr 2016 Planned End Date changed from 1 May 2017 to 1 Sep 2017 as reported by ClinicalTrials.gov.
    • 11 Apr 2016 Planned primary completion date changed from 1 May 2017 to 1 Sep 2017 as reported by ClinicalTrials.gov.
    • 13 Oct 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top